文献速递系统性红斑狼疮其他结缔组织病

系统性红斑狼疮患者中预存中和IFN-α自身抗体者疾病活动度较低但重症COVID-19和带状疱疹风险较高

Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
PubMed 文献 · Ann Rheum Dis · 2022-08-16

该研究回顾性分析609例系统性红斑狼疮患者的单中心纵向队列,发现中和性抗IFN-α抗体频率为3.3%、非中和性为8.4%,中和性抗体与IFN-α血清水平降低和活动性疾病可能性降低相关,但增加带状疱疹和重症COVID-19肺炎风险,且不干扰COVID-19疫苗体液免疫原性。

要点

  • 系统性红斑狼疮患者中中和性抗IFN-α抗体频率为3.3%,非中和性为8.4%。
  • 中和性抗IFN-α抗体与IFN-α血清水平降低和活动性疾病可能性降低相关。
  • 中和性抗IFN-α抗体增加带状疱疹和重症COVID-19肺炎风险,但不干扰COVID-19疫苗体液免疫原性。

核心结论

  • 系统性红斑狼疮中非中和性和中和性抗I型干扰素抗体的产生可能是系统性红斑狼疮相关高I型干扰素血清水平的后果,对疾病活动度有益但病毒风险更大。
  • 该发现强化了系统性红斑狼疮中接种SARS-CoV-2疫苗的建议。

研究设计与样本

  • 回顾性分析单中心纵向队列,纳入609例系统性红斑狼疮患者。
  • 血清抗IFN-α抗体通过ELISA定量,并通过消除Madin-Darby牛肾细胞对IFN-α2抗水疱性口炎病毒挑战的保护作用进行功能评估。
  • 血清对IFN-α2、IFN-β和IFN-ω的中和活性通过报告基因荧光素酶活性测定确定。
  • SARS-CoV-2抗体反应针对野生型刺突抗原测量,血清中和活性针对SARS-CoV-2历史毒株和关注变异株评估。

主要发现

  • 系统性红斑狼疮个体中中和性和非中和性抗IFN-α抗体频率分别为3.3%和8.4%。
  • 中和性抗IFN-α抗体(不同于非中和性抗体)与IFN-α血清水平降低和发生活动性疾病的可能性降低相关。
  • 中和性抗IFN-α抗体使患者易患带状疱疹和重症COVID-19肺炎风险增加。
  • 系统性红斑狼疮患者的重症COVID-19肺炎主要与不同I型干扰素的联合中和相关。
  • 抗IFN-α自身抗体不干扰COVID-19疫苗体液免疫原性。

临床怎么用

  • 该发现强化了系统性红斑狼疮中接种SARS-CoV-2疫苗的建议。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Type-I interferons (IFNs-I) have potent antiviral effects. IFNs-I are also overproduced in patients with systemic lupus erythematosus (SLE). Autoantibodies (AAbs) neutralising IFN-α, IFN-β and/or IFN-ω subtypes are strong determinants of hypoxemic COVID-19 pneumonia, but their impact on inflammation remains unknown. METHODS: We retrospectively analysed a monocentric longitudinal cohort of 609 patients with SLE. Serum AAbs against IFN-α were quantified by ELISA and functionally assessed by abolishment of Madin-Darby bovine kidney cell protection by IFN-α2 against vesicular stomatitis virus challenge. Serum-neutralising activity against IFN-α2, IFN-β and IFN-ω was also determined with a reporter luciferase activity assay. SARS-CoV-2 antibody responses were measured against wild-type spike antigen, while serum-neutralising activity was assessed against the SARS-CoV-2 historical strain and variants of concerns. RESULTS: Neutralising and non-neutralising anti-IFN-α antibodies are present at a frequency of 3.3% and 8.4%, respectively, in individuals with SLE. AAbs neutralising IFN-α, unlike non-neutralising AAbs, are associated with reduced IFN-α serum levels and a reduced likelihood to develop active disease. However, they predispose patients to an increased risk of herpes zoster and severe COVID-19 pneumonia. Severe COVID-19 pneumonia in patients with SLE is mostly associated with combined neutralisation of different IFNs-I. Finally, anti-IFN-α AAbs do not interfere with COVID-19 vaccine humoral immunogenicity. CONCLUSION: The production of non-neutralising and neutralising anti-IFN-I antibodies in SLE is likely to be a consequence of SLE-associated high IFN-I serum levels, with a beneficial effect on disease activity, yet a greater viral risk. This finding reinforces the recommendations for vaccination against SARS-CoV-2 in SLE.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mathian A, Breillat P, Dorgham K, et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis. 2022. PMID: 35973806. doi:10.1136/ard-2022-222549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。